Summary
- Isomorphic Labs raised $5 billion in a Series C funding round.
- The company spun out of Google's DeepMind division in 2021.
- Funds will support efforts to move drug candidates into clinical trials.
Isomorphic Labs has closed a $5 billion Series C funding round, one of the largest sums ever raised by a company applying artificial intelligence to drug discovery. The London-based firm, spun out of Google's DeepMind in 2021, built its technology on the foundation of AlphaFold, the protein-structure prediction system that earned its creators a Nobel Prize. The new capital is earmarked for advancing the company's drug candidates out of the lab and into human clinical trials, a step that has historically proven far more difficult and expensive than computational modeling alone.
The round underscores a shift in how investors view AI's role in pharmaceuticals. For years, AI drug-discovery startups positioned themselves as tools to speed up early-stage research, helping scientists identify promising molecules faster than traditional trial-and-error methods. Isomorphic Labs has pitched itself more ambitiously, aiming to design drugs computationally with enough confidence to skip some of the slower, costlier phases of conventional development. Reaching clinical trials would mark a critical proof point for that pitch, since no amount of simulated accuracy matters commercially unless a drug candidate survives contact with human biology.
The scale of the raise also reflects how capital-intensive biotech remains, even when AI is doing much of the early heavy lifting. Clinical trials routinely cost hundreds of millions of dollars per drug candidate and can take years to produce results, win regulatory approval, or fail outright. A $5 billion war chest gives Isomorphic Labs runway to pursue multiple candidates simultaneously without depending on a pharmaceutical partner to foot every bill, a notable shift for a company that has previously worked alongside major drugmakers rather than going it alone.
Isomorphic Labs' rise also reflects Google's broader strategy of spinning out DeepMind research into standalone, commercially focused ventures. By operating independently while still drawing on DeepMind's AI advances, the company has attracted investor interest separate from Alphabet's own balance sheet, allowing it to raise enormous sums without diluting its parent company's shares.
The funding arrives at a moment when AI's application to biology is drawing intense scrutiny over whether its promises can translate into approved treatments. Dozens of AI-driven biotech startups have launched in recent years, but few have advanced candidates deep into clinical testing, and setbacks remain common across the industry. How Isomorphic Labs' pipeline performs in trials over the coming months and years will serve as a closely watched test case for whether AI-designed drugs can meet the same regulatory bar as those developed through conventional methods, and whether investor enthusiasm for the sector is matched by clinical results.
